Press Releases

Month Year

Month Year

Nov 30, 2022

Sanofi to present new clinical data reinforcing novel therapies across rare blood disorders at ASH 2022
Oct 6, 2022

Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes
Sep 28, 2022

Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis

Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials
Sep 8, 2022

Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis
Aug 31, 2022

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)

Show per page

Print
Email page
RSS